What was the purpose of Amgen's debt offering?

While the filing doesn't explicitly state the purpose, significant debt offerings are often used to strengthen a company's balance sheet, fund capital expenditures, support research and development, or facilitate acquisitions.

What does 'adjusted earnings per share' mean and why is it used?

Adjusted EPS is a non-GAAP measure that excludes certain items the company deems unusual or non-recurring, such as stock option expenses and specific acquisition-related costs. Companies use it to present a view of ongoing operational performance, though investors should always consider the impact of these excluded items and compare it to GAAP EPS.

What is the significance of the negative credit watch and outlook from S&P and Moody's?

A negative credit watch or outlook suggests that rating agencies see potential for a downgrade in Amgen's credit rating in the future. This could be due to various factors not detailed in this specific filing, but it indicates increased perceived risk regarding the company's financial stability or future performance, which could impact borrowing costs.

How does the expected Centers for Medicare and Medicaid Services (CMS) determination in August 2007 affect the EPS guidance?

The filing states that the 2007 EPS guidance is subject to future events, including the CMS national coverage determination. This implies that the outcome of this determination could materially impact the company's revenues and profitability, potentially affecting the actual EPS achieved for the year.

AMGN 8-K: Regulation FD

Summary

Amgen Inc. filed an 8-K report on May 25, 2007, detailing significant financial activities and guidance updates. The company announced the successful pricing of a substantial debt offering, raising $4.0 billion through the issuance of Senior Floating Rate Notes due 2008, 5.85% Senior Notes due 2017, and 6.375% Senior Notes due 2037. This move aims to strengthen the company's financial position and potentially fund future operations or acquisitions. Furthermore, Amgen provided an updated outlook for its 2007 fiscal year, indicating that its adjusted earnings per share (EPS) is tracking in line with the previously projected $4.30. This guidance excludes stock option expenses and certain other charges, notably those related to past acquisitions. The company also highlighted its proactive cost management by disclosing that it has already achieved significant operating expense reductions for 2007 and retains the flexibility for further adjustments if market conditions necessitate. Investors should note the concurrent credit rating reviews by S&P and Moody's, which, while confirming existing ratings, placed them on negative watch or outlook, reflecting potential future concerns.

Key Highlights

1Amgen priced a $4.0 billion debt offering, including $2.0 billion in Senior Floating Rate Notes due 2008, $1.1 billion in 5.85% Senior Notes due 2017, and $900 million in 6.375% Senior Notes due 2037.
2The company reaffirmed its 2007 adjusted EPS guidance of $4.30, based on current sales and expense trends.
3Adjusted EPS guidance excludes stock option expense, certain acquisition-related costs (Immunex, Tularik, Abgenix, Avidia), and other specified items.
4Amgen has already reduced its 2007 budgeted operating expenses by $600 million to $800 million and maintains flexibility for further reductions.
5Standard & Poor's confirmed its A+ senior unsecured debt rating but placed it on credit watch with negative implications.
6Moody's Investors Service confirmed its A2 senior unsecured debt rating but revised the outlook to negative from stable.

AMGEN INC 8-K Report, Regulation FD Disclosure (May 25, 2007)

Summary

Key Highlights

Frequently Asked Questions